Rohaan, Maartje W; Borch, Troels H; van den Berg, Joost H; Met, Özcan; Kessels, Rob; Geukes Foppen, Marnix H; Stoltenborg Granhøj, Joachim; Nuijen, Bastiaan; Nijenhuis, Cynthia; Jedema, Inge; van Zon, Maaike; Scheij, Saskia; Beijnen, Jos H; Hansen, Marten; Voermans, Carlijn; Noringriis, Inge M; Monberg, Tine J; Holmstroem, Rikke B; Wever, Lidwina D V; van Dijk, Marloes; Grijpink-Ongering, Lindsay G; Valkenet, Ludy H M; Torres Acosta, Alejandro; Karger, Matthias; Borgers, Jessica S W; Ten Ham, Renske M T; Retèl, Valesca P; van Harten, Wim H; Lalezari, Ferry; van Tinteren, Harm; van der Veldt, Astrid A M; Hospers, Geke A P; Stevense-den Boer, Marion A M; Suijkerbuijk, Karijn P M; Aarts, Maureen J B; Piersma, Djura; van den Eertwegh, Alfons J M; de Groot, Jan-Willem B; Vreugdenhil, Gerard; Kapiteijn, Ellen; Boers-Sonderen, Marye J; Fiets, W Edward; van den Berkmortel, Franchette W P J; Ellebaek, Eva; Hölmich, Lisbet R; van Akkooi, Alexander C J; van Houdt, Winan J; Wouters, Michel W J M; van Thienen, Johannes V; Blank, Christian U; Meerveld-Eggink, Aafke; Klobuch, Sebastian; Wilgenhof, Sofie; Schumacher, Ton N; Donia, Marco; Svane, Inge Marie; Haanen, John B A G
(Massachussetts Medical Society, 2022-12-08)
Background Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials ...